izpis_h1_title_alt

Vaccinomics and adversomics in the era of precision medicine : a review based on HBV, MMR, HPV, and COVID-19 vaccines
ID Omersel, Jasna (Avtor), ID Karas Kuželički, Nataša (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,21 MB)
MD5: 2E038FCD3D785D335EE1283AB9340AAE
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2077-0383/9/11/3561 Povezava se odpre v novem oknu

Izvleček
Precision medicine approaches based on pharmacogenomics are now being successfully implemented to enable physicians to predict more efficient treatments and prevention strategies for a given disease based on the genetic background of the patient. This approach has already been proposed for vaccines, but research is lagging behind the needs of society, and precision medicine is far from being implemented here. While vaccinomics concerns the effectiveness of vaccines, adversomics concerns their side effects. This area has great potential to address public concerns about vaccine safety and to promote increased public confidence, higher vaccination rates, and fewer serious adverse events in genetically predisposed individuals. The aim here is to explore the contemporary scientific literature related to the vaccinomic and adversomic aspects of the three most-controversial vaccines: those against hepatitis B, against measles, mumps, and rubella, and against human Papilloma virus. We provide detailed information on the genes that encode human leukocyte antigen, cytokines and their receptors, and transcription factors and regulators associated with the efficacy and safety of the Hepatitis B and Measles, Mumps and Rubella virus vaccines. We also investigate the future prospects of vaccinomics and adversomics of a COVID-19 vaccine, which might represent the fastest development of a vaccine ever.

Jezik:Angleški jezik
Ključne besede:adversomics, COVID-19, genetics, hepatitis B, human Papilloma virus, MMR vaccine, precision medicine, vaccinomics
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2020
Št. strani:22 str.
Številčenje:Vol. 9, iss. 11, art. 3561
PID:20.500.12556/RUL-134726 Povezava se odpre v novem oknu
UDK:615.015:575.111
ISSN pri članku:2077-0383
DOI:10.3390/jcm9113561 Povezava se odpre v novem oknu
COBISS.SI-ID:35836931 Povezava se odpre v novem oknu
Datum objave v RUL:27.01.2022
Število ogledov:779
Število prenosov:229
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Journal of clinical medicine
Skrajšan naslov:J. clin. med.
Založnik:MDPI
ISSN:2077-0383
COBISS.SI-ID:5405759 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:05.11.2020

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:genomika, farmakogenomika, cepiva, stranski učinki, humani papilomavirus, hepatitis B

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj